Search

Your search keyword '"Zhouchao Hu"' showing total 3 results
Start Over Author "Zhouchao Hu"
3 results on '"Zhouchao Hu"'

1. One‐year status of hepatic venous pressure gradient measurement from 85 hospitals in China

Author

Jitao Wang, Ting Cui, Linpeng Zhang, Zhiping Yan, Lei Li, Jinjun Chen, Junhui Sun, Hua Xiang, He Zhu, Hao Wu, Jiancuo Gengzang, Feng Zhang, Wei Wu, Guohong Cao, Wuhua Guo, Haibin Shi, Hui Xue, Guangjun Huang, Qiang Yu, Meng Niu, Huiling Xiang, Derun Kong, Wei Gou, Xuefeng Luo, Fuliang He, Min Yuan, Wei Liu, Yong Wang, Hongjie Hu, Xiaoli Zhu, Tao Yu, Qinxue Sun, Wei Qu, Ting Lu, Deqiang Ma, Li Zhang, Jun Ma, Jun Yang, Ketao Mu, Xiaoliang Zhu, Kai Xiong, Huiguo Ding, Shengjuan Yao, Mingsheng Huang, Fang Wang, Zexin Wang, Yong Huang, Jianan Li, Hongfeng Yi, Birun Huang, Zhongwei Zhao, Duiping Feng, Yanming Lei, Changlong Hou, Wenbo Guo, Shirong Liu, Gaojun Teng, Kangshun Zhu, Fan Wu, Xiaogang Hu, Wenfeng Zhang, Shaoqi Yang, Zhouchao Hu, Pengfei Pang, Shaowu Zhuang, Weidong Wang, Qingliang Zhu, Kunpeng Zhang, Chengyu Liu, Dongliang Li, Chao Ma, Hong Jiang, Xingong Zhao, Weixin Ren, Zhiwei Wang, Lei Yu, Fuhuang Lin, Chaoguang Yan, Feng Wang, Hui Huan, Wenyong Shen, Shaofei He, Chengda Zhang, Jinlun Bao, Jiangtao Liu, Jun Wu, Jianbo Zhao, Jian Zhang, and Xiaolong Qi

Subjects
application status, hepatic vein pressure gradient, questionnaire survey, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Aims Surveys and research on the applications of the hepatic venous pressure gradient (HVPG) are important for understanding the current status and future development of this technology in China. This article aimed to investigate the status of hepatic venous pressure gradient measurement in China in 2022. Methods We investigated the overall status of HVPG technology in China—including hospital distribution, hospital level, annual number of cases, catheters used, average cost, indications, and current challenges by using online questionnaire. By counting the number and percentages of cases of these results, we hope to clarify the current status of HVPG measurements in China. Results According to the survey, 85 hospitals in China used HVPG technology in 2022 distributed across 29 provinces. A total of 4989 HVPG measurements were performed in all of the surveyed hospitals in 2022, of which 2813 cases (56.4%) were measured alone. The average cost of HVPG measurement was 5646.8 ± 2327.9 CNY. Of the clinical teams who performed the measurements (sometimes multiple per hospital), 94.3% (82/87) used the balloon method, and the majority of the teams (72.4%, 63/87) used embolectomy catheters. Conclusions This survey clarified the clinical application status of HVPG in China and confirmed that some medical institutions in China have established a foundation for this technology. It is still necessary to continue promoting and popularizing this technology in the future.

Published
2024
Full Text
View/download PDF

2. Pre-radiofrequency ablation MRI imaging features predict the local tumor progression in hepatocellular carcinoma

Author

He-ping Wang, Jingang Yan, Zhang Guoqiang, Shibo Li, Zhouchao Hu, and Nannan Yu

Subjects
Male, Carcinoma, Hepatocellular, Radiofrequency ablation, Observational Study, law.invention, nomogram, 03 medical and health sciences, 0302 clinical medicine, law, Preoperative Care, Carcinoma, Humans, Medicine, Effective diffusion coefficient, 030212 general & internal medicine, Radiofrequency Ablation, business.industry, Proportional hazards model, Liver Neoplasms, Hazard ratio, Reproducibility of Results, General Medicine, Middle Aged, Nomogram, Prognosis, medicine.disease, Magnetic Resonance Imaging, radiofreqeuncy ablation, local tumor progression, Nomograms, Liver, Tumor progression, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Female, Neoplasm Recurrence, Local, business, Nuclear medicine, Research Article
Abstract

To investigate whether MRI features could preoperatively predict local tumor progression (LTP) in patients with hepatocellular carcinoma (HCC) treated with radiofrequency ablation (RFA) as the first-line treatment and improve a novel predictive model through developing a nomogram including various conventional MRI parameters. 105 patients with HCCs who had received RFA were enrolled. All patients had undergone conventional MRI before RFA. Uni- and multivariable analyses for LTP were assessing using a Cox proportional hazards model. The developed MRI-based nomogram was further designed based on multivariable logistic analysis in our study and the usefulness of the developed model was validated according to calibration curves and the C-index. Rim enhancement (hazard ratio: 2.689, P = .044) and the apparent diffusion coefficient (ADC) values (hazard ratio: 0.055, P = .038) were statistically significant independent predictors of LTP after RFA at multivariable analysis. The performance of the nomogram incorporating two MRI parameters (with a C-index of 0.782) was improved compared with that based on rim enhancement and ADC alone (with C-index values of 0.630 and 0.728, respectively). The calibration curve of the MRI-based nomogram showed good conformance between evaluation and observation at 0.5, 1, and 1.5 years after RFA. The preliminary predictive model based on MRI findings including rim enhancement and ADC value could be used preoperatively to estimate the risk of LTP of HCC after RFA as the first-line treatment.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results